Premium
Extracorporeal Bioartificial Liver Using the Radial‐flow Bioreactor in Treatment of Fatal Experimental Hepatic Encephalopathy
Author(s) -
Kanai Hideki,
Marushima Hideki,
Kimura Naofumi,
Iwaki Takamasa,
Saito Masaya,
Maehashi Haruka,
Shimizu Keiko,
Muto Makiko,
Masaki Takahiro,
Ohkawa Kiyoshi,
Yokoyama Keitaro,
Nakayama Masaaki,
Harada Tohru,
Hano Hiroshi,
Hataba Yoshiaki,
Fukuda Takahiro,
Nakamura Masahiko,
Totsuka Naoto,
Ishikawa Shutaro,
Unemura Yasuki,
Ishii Yuji,
Yanaga Katsuhiko,
Matsuura Tomokazu
Publication year - 2007
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2007.00354.x
Subject(s) - bioartificial liver device , hepatic encephalopathy , extracorporeal , encephalopathy , medicine , liver failure , pathology , biology , hepatocyte , cirrhosis , biochemistry , in vitro
An extracorporeal bioartificial liver (BAL) that could prevent death from hepatic encephalopathy in acute hepatic insufficiency was aimed to develop. A functional human hepatocellular carcinoma cell line (FLC‐4) was cultured in a radial‐flow bioreactor. The function of the BAL was tested in mini‐pigs with acute hepatic failure induced by α‐amanitin and lipopolysaccharide. When the BAL system was connected with cultured FLC‐4 to three pigs with hepatic dysfunction, all demonstrated electroencephalographic improvement and survived. Relatively low plasma concentrations of S‐100 β protein, as a marker of astrocytic damage, from pigs with hepatic failure during BAL therapy were noted. BAL therapy can prevent irreversible brain damage from hepatic encephalopathy in experimental acute hepatic failure.